Skip to main content

nirmatrelvir and ritonavir Medicare Part D Coverage

Brand name: Paxlovid
Dosage form
KIT
99%
of Medicare Part D plans
cover nirmatrelvir and ritonavir
5,496 of 5,530 plans
3.2
Avg. formulary tier
$15.00
Median 30-day copay
$0.00–$30.00
Copay range

Formulary Tier Distribution

How Medicare Part D plans classify nirmatrelvir and ritonavir. Lower tiers = lower copays.

Tier 1 - Preferred Generic 5%
261 plans • avg $0.00/mo
Tier 2 - Generic 16%
893 plans • avg $1.04/mo
Tier 3 - Preferred Brand 58%
3,173 plans • avg $4.65/mo
Tier 5 - Specialty 21%
1,159 plans • avg $0.00/mo
Tier 6 - Select Care 0%
10 plans • avg $0.00/mo

Find the cheapest plan for nirmatrelvir and ritonavir

Enter your ZIP code to compare every plan in your area side-by-side.

Compare Plans for nirmatrelvir and ritonavir →

Get nirmatrelvir and ritonavir Delivered to Your Door

Compare prices and get discounts from trusted online pharmacies

DrugCovered may earn commissions from pharmacy purchases. Prices and availability vary. Always consult your doctor before starting or changing medications.

nirmatrelvir and ritonavir Medicare Coverage by State

Coverage rates and average costs vary significantly by state. Click a state to see the specific plans available there.

Frequently Asked Questions about nirmatrelvir and ritonavir

99% of Medicare Part D plans cover nirmatrelvir and ritonavir. It is most commonly placed on Tier 3. Coverage varies by plan and geographic area.

The median 30-day copay for nirmatrelvir and ritonavir on Medicare Part D is $15.00 at a preferred pharmacy. Costs range from $0.00 to $30.00 depending on the plan.

nirmatrelvir and ritonavir is placed on Tier 3 by most Medicare Part D plans. Lower tier numbers generally mean lower copays.

0% of plans require prior authorization for nirmatrelvir and ritonavir. Prior authorization means your doctor must confirm the drug is medically necessary before the plan will cover it.

Coverage statistics based on CMS formulary data for plan year 2026. Data updated regularly. Methodology →